In November 2018, the United Kingdom moved to reschedule Cannabis-Based Products for Medicinal Use (CBPM) from Schedule 1 to Schedule 2 under the Misuse of Drugs Regulations 2001. For many, this was framed as a liberation. In reality, it was a administrative shift—one that created a narrow, hyper-regulated corridor for access that remains one of the most confusing landscapes in modern medicine.
Having spent over a decade covering healthcare policy across the UK and Canada, I have grown accustomed to the "policy gap"—the space durhampost between what a government claims to provide and what a patient actually experiences. In the UK, that gap is currently being filled by private digital clinics. These clinics have become the de facto gatekeepers of the CBPM ecosystem, and they carry a significant, largely unscrutinised burden: they are the primary source of patient education.
The 2018 Legalization: A Study in Cautious Adoption
When the UK government legalized medical cannabis, it did so with immense caution. The National Institute for Health and Care Excellence (NICE)—the body that determines what is cost-effective for the National Health Service (NHS)—issued guidelines that were essentially restrictive. They focused on narrow conditions like refractory epilepsy and multiple sclerosis.
The result was predictable. NHS doctors, fearing regulatory backlash and lacking specialized knowledge, simply stopped prescribing. If you are a patient in the UK expecting your GP (General Practitioner) to help you navigate cannabis-based treatment, you are likely to be disappointed. This is not a matter of opinion; it is a matter of clinical workflow. The NHS has not built the infrastructure to support these prescriptions.
Consequently, access moved entirely to the private sector. If a patient wants access, they must navigate the private clinic landscape. In this space, the burden of "patient education" has shifted from the public health system to the digital clinics themselves.
Digital-First Clinics: Service or Sales?
The growth of digital-first clinics has been rapid. We have seen a proliferation of providers who utilize telehealth platforms to bridge the geographical divide. These clinics promise accessibility, but as a journalist, I find it necessary to distinguish between a "clinical pathway" and a "brand statement."
Many clinics describe their patient education resources as "holistic support." In reality, these resources are often the only material a patient receives to understand their treatment pathway. When a patient signs up for a clinic, they are given access to a patient portal. This is where they book their initial consultation, fill out intake forms, and store their medical history.
However, there is a clear tension here. These clinics are businesses. When they provide educational pamphlets, webinars, or blog posts about the efficacy of specific cannabis strains or delivery methods, are they acting as clinicians or as commercial entities? The line is thin.
The Role of Remote Consultations
Modern clinics rely heavily on encrypted video appointments. The technological standard is generally high—most platforms meet the necessary security protocols to protect patient data under the UK General Data Protection Regulation (GDPR). But the technology is not the treatment. It is merely the conduit.
The workflow typically follows this pattern:
Screening: Initial digital intake via a patient portal. Consultation: An encrypted video appointment with a specialist doctor. Review: The decision by the Multi-Disciplinary Team (MDT) to approve or deny treatment. Prescription: The electronic transfer of the prescription to a specialized pharmacy.The "education" happens between the consultation and the prescription. The patient is often left to research their own potential medicine from a list of available products. In this model, the patient becomes their own researcher. They rely on clinic information to decide which product might suit their physiology. This is highly unusual compared to standard NHS pharmaceutical practice, where a doctor selects the drug and the dose based on a clinical formulary.
Comparative Analysis: NHS Pathways vs. Private Clinic Access
To understand why patient education has become such a contentious issue, we must compare the two modes of access. The table below outlines the structural differences in how treatment information is disseminated.
Feature NHS Pathway Private Clinic Pathway Primary Information Source NHS Clinical Guidelines (NICE) Clinic-curated education resources Doctor's Role Decision-maker / Provider Prescriber / Facilitator Product Selection Standardized formulary Patient/Doctor consensus from varied stock Transparency of Education High (Publicly audited) Variable (Dependent on clinic ethos)Addressing the Education Gap
I am often asked if these clinics do a good job of educating their patients. My answer is that they do a good job of providing "onboarding" materials, but they are often lacking in unbiased, comparative clinical data.
Because these clinics often act as the pharmacy’s partner, the clinic information provided to the patient can sometimes favour the brands that the clinic has supply chain agreements with. This is not necessarily illegal, but it is a conflict of interest that patients are rarely alerted to.
The reliance on these digital portals creates a feedback loop. A patient logs into their portal, sees an article written by the clinic about the benefits of a certain cannabinoid ratio, and then discusses that specific product with their doctor during an encrypted video appointment. The clinic has successfully "educated" the patient into a sale. This is not medicine; this is targeted marketing disguised as care.
Legally Sensitive Considerations
When discussing these matters, it is crucial to stay within the boundaries of current UK law. The law does not mandate that private clinics provide independent education. The Care Quality Commission (CQC), which regulates health and social care in England, ensures that clinics are safe and follow best practices. However, the CQC is not a watchdog for medical marketing or the quality of educational content provided by these companies.
The legal environment is strict. Providing medical advice that is not backed by evidence is a risk. Clinics know this. Therefore, you will notice that most "educational" posts on clinic websites come with heavy disclaimers. These disclaimers are not just legal boilerplate; they are admissions that the information provided is not a substitute for formal, evidence-based clinical guidance.
Is the Current Reliance on Private Clinics Sustainable?
The reliance on private clinic education is a stopgap measure, not a permanent solution. As the market for medical cannabis matures, we must address three critical flaws in the current digital-first approach:
- Data Silos: Patient data is trapped within individual clinic portals, preventing the creation of a national registry that could provide better, evidence-based education. Lack of Standardization: One clinic’s "educational resources" might look like a peer-reviewed guide, while another’s looks like a lifestyle blog. The Cost of Access: Private care is expensive. The high cost of consultations and repeat prescription fees effectively turns medicine into a luxury good for the informed.
Medical cannabis is not a lifestyle trend. It is a complex pharmacotherapy that requires stringent monitoring. By allowing the "education" of patients to become a proprietary, branded service, the UK has essentially abdicated its responsibility to provide neutral, high-quality medical information to those who need it most.
Final Thoughts
If you are a patient looking for treatment, you must approach clinic information with a high degree of skepticism. Treat the educational resources as you would a brochure from a luxury car dealer: informative, but designed to lead you toward a specific purchase. Use the telehealth tools for their intended purpose—accessing a doctor—but do not expect those platforms to act as your primary source of impartial medical truth.
The NHS may be the gold standard, but it is currently invisible to the majority of medical cannabis patients. Until that changes, the burden of literacy—the requirement to understand the medicine, the risks, and the alternatives—falls squarely on the patient. It is a heavy burden, and one that the current private, digital-first system is not fully equipped to carry fairly.